2022 (96 POSTS)
Movva N, Suh M, Reichert H , Hitze B, Sendak MP, Wolf Z, et al. 2022. Respiratory syncytial virus during the COVID-19 pandemic compared to historic levels: A retrospective cohort study of a health system. J Infect Dis 226(Suppl 2):S175–S183; doi: 10.1093/infdis/jiac220 . PMID: 35968868.
View Abstract
Topics: COVID-19 , Epidemiology
Suh M, Movva N, Jiang X, Bylsma LC, Reichert H, Fryzek JP, Nelson CB. 2022. Respiratory syncytial virus (RSV) is the leading cause of United States infant hospitalizations 2009–2019: A study of the National (Nationwide) Inpatient Sample. J Infect Dis 226(Suppl 2):S154–S163; doi: 10.1093/infdis/jiac120 . PMID: 35968878.
View Abstract
Topics: Epidemiology
Wheeler MW , Cortiñas Abrahantes J, Aerts M, Gift JS, Allen Davis J. 2022. Continuous model averaging for benchmark dose analysis: Averaging over distributional forms. Environmetrics 33(5):e2728; doi: 10.1002/env.2728 . PMCID: PMC9799099.
View Abstract
Topics: benchmark dose estimation (BMD) , dose-response , modeling , risk analysis
House JS, Grimm FA, Klaren WD , Dalzell A, Kuchi S, Zhang S, Lenz K, Boogaard PJ, Ketelsegers HB, Gant TW, Wright FA, Rusyn I. 2022. Grouping of UVCB substances with dose-response transcriptomics data from human cell-based assays. ALTEX 39(3):388-404; doi: 10.14573/altex.2107051 . PMID: 35288757.
View Abstract
Topics: Toxicology
Rankin DA, Haddadin Z, Lipworth L, Stahl AL, Fryzek J, Suh M , et al. 2022. Comparison of clinical presentations and burden of respiratory syncytial virus in infants across three distinct healthcare settings in Davidson County, Tennessee. Therapeut Adv Infect Dis 9(July 18):20499361221112171; doi: 10.1177/20499361221112171 . PMID: 35875809.
View Abstract
Topics: Epidemiology
Ponder J, Rajagopal R, Singal M, Baker N, Patlewicz G , Roggen E, Cochrane S, Sullivan K. 2022. “In Litero” screening. Retrospective evaluation of clinical evidence to establish a reference list of human chemical respiratory sensitizers. Front Toxicol 4(Jul 15):916370; doi: 10.3389/ftox.2022.916370 . PMID: 35910543.
View Abstract
Topics: Adverse outcome pathways (AOPs) , NAMs
Gupta N, Patel HD, Taylor J, Borin JF, Jacobsohn K,…, Price C , et al. 2022. Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes. Prostate Cancer Prostatic Dis 25(3):444–452; doi: 10.1038/s41391-022-00553-2 .
View Abstract
Topics: Cancer , Systematic Review
Karmaus A, Mansouri K, To K, Blake B, Fitzpatrick J, Strickland J, Patlewicz G , Allen D, et al. 2022. Evaluation of variability across rat acute oral systemic toxicity studies. Toxicol Sci 188(1):34-47; doi: 10.1093/toxsci/kfac042 . PMID: 35426934.
View Abstract
Topics: NAMs
Tsvetkov L, Pittsenbarger J, Atsriku C, Devine P, Dingley K , et al. 2022. Inhibition of CDC7 with Sgr-2921 in AML models results in enhanced DNA damage and anti-leukemic activity as monotherapy and in combination with standard of care agents. Blood 140 (Supplement 1):5961–5962; doi: 10.1182/blood-2022-167239.
View Abstract
Topics: Cancer
Roell K, Koval LE, Boyles R, Patlewicz G , Ring C, Rider CV, Ward-Caviness C, Reif D, et al. 2022. Development of the intelligence and machine learning toolkit (TAME) for introductory data science, chemical-biological analyses, predictive modelling, and database mining for environmental health research. Front Toxicol 4(Jun 22):893924; doi: 10.3389/ftox.2022.893924 . PMID: 35812168.
View Abstract
Topics: computational toxicology , Epidemiology , Exposure Assessment
Jensen IS , Wu E, Cyr PL , Claussen M, Winkler T, Salahuddin K, Prats J, et al. 2022. Cost-consequence analysis of using cangrelor in high angiographic risk percutaneous coronary intervention patients: A US hospital perspective. Am J Cardiovasc Drugs 22(1):93-104; doi: 10.1007/s40256-021-00491-9 . PMID: 34331235.
View Abstract
Topics: Health Economics and Outcomes Research (HEOR)
Alexander AW, Jensen IJ , Hathaway J, Srivastava K, Cyr PL , Sidonio RF, Batt K. 2022. Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements. J Manag Care Spec Pharm 28(5):518-527; doi: 10.18553/jmcp.2022.21197 . PMID: 35343812.
View Abstract
Topics: Health Economics and Outcomes Research (HEOR)
Price C . 2022. Syntheses synthesized: A look back at Grant and Booth’s review typology. Evid-based Libr Info Prac 17(2):132–138; doi: 10.18438/eblip30093.
View Abstract
Topics: Systematic Review
Coppi A, Davies R, Wegesser T, Ishida K, Karmel J, Han J, Aiello F, Xie Y…, Monticello TM , et al. 2022. Characterization of false positive, contaminant- driven mutagenicity in impurities associated with the sotorasib drug substance. Regul Toxicol Pharmacol 131(June):105162; doi: 10.1016/j.yrtph.2022.105162 .
View Abstract
Topics: drug development
Reynolds JI , Vitek RA, Geiger PG, Johnson BP. 2022. Engineering epithelial-mesenchymal microtissues to study cell-cell interactions in development. Methods Med Biol 2403:201-213; doi: 10.1007/978-1-0716-1847-9_13 . PMID: 34913124.
View Abstract
Flannery BM, Schaefer HR , Middleton KB. 2022. A scoping review of infant and children health effects associated with cadmium exposure. Regul Toxicol Pharmacol 131(Jun):105155; doi: 10.1016/j.yrtph.2022.105155 . PMID: 35257832.
View Abstract
Topics: cadmium , Exposure Assessment
Rivera BN , Wilson LB, Kim DM, Pande P, Anderson KA, Tilton SC, Tanguay RL. 2022. A comparative multi-system approach to characterizing bioactivity of commonly occurring chemicals. Int J Environ Res Public Health 19(7):3829; doi: 10.3390/ijerph19073829 . PMID: 35409514.
View Abstract
Topics: chemical safety assessment , modeling
Lea IA , Pham LL, Antonijevic T, Thompson C , Borghoff SJ . 2022. Assessment of the applicability of the threshold of toxicological concern for per- and polyfluoroalkyl substances. Regul Toxicol Pharmacol 133(August):105190; doi: 10.1016/j.yrtph.2022.105190 . PMID: 35662637.
View Abstract
Topics: PFAS
Sacks NC , Healey BE, Raza S, Cyr PL , Boerner G, Sheshadri A. 2022. The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States. Blood Adv 6(5):1566–1576; doi: 10.1182/bloodadvances.2021004364 . PMID: 34807973.
View Abstract